Plain-English translation of NCT01776905 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Researchers are testing a new imaging device designed to detect melanoma cancer cells circulating in the blood. This study will compare the new device to standard blood tests in people with melanoma at different stages, as well as in healthy volunteers. The goal is to see if this device can find melanoma cells earlier and more accurately than current methods.
Current blood tests have limits in detecting melanoma cells, especially in early stages of the disease. This trial exists to see if a new imaging technology can find these cells more reliably and at lower concentrations, which could help catch melanoma earlier when treatment is more effective.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic for an imaging scan using the new device, which takes about 90 minutes while you sit still. The researchers will also draw blood samples to run standard tests for comparison. Depending on which group you join (healthy volunteer, early-stage melanoma, or advanced melanoma), your specific visits and timing may vary, but the core activities are the same: the imaging scan and blood draws.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States
Enrollment target
~75 participants
Started
February 2013
Primary completion
July 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jumin Sunde, MD
University of Arkansas
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.